Liquid Biopsies - The Clinics and the Molecules

J 2017

Liquid Biopsies - The Clinics and the Molecules

KUBACZKOVÁ, Veronika, Lenka SEDLAŘÍKOVÁ, Božena BOLLOVÁ, Viera SANDECKÁ, Martin ŠTORK et. al.

Základní údaje

Originální název

Liquid Biopsies - The Clinics and the Molecules

Autoři

KUBACZKOVÁ, Veronika (203 Česká republika, domácí), Lenka SEDLAŘÍKOVÁ (203 Česká republika, domácí), Božena BOLLOVÁ (703 Slovensko, domácí), Viera SANDECKÁ (703 Slovensko), Martin ŠTORK (203 Česká republika), Luděk POUR (203 Česká republika) a Sabina ŠEVČÍKOVÁ (203 Česká republika, garant, domácí)

Vydání

Klinická onkologie, Praha, Ambit Media, 2017, 0862-495X

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Česká republika

Utajení

není předmětem státního či obchodního tajemství

Kód RIV

RIV/00216224:14110/17:00095663

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.14735/amko20172S13

Klíčová slova anglicky

cell-free DNA non-coding RNA; liquid biopsies; minimal residual disease; multiple myeloma

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 22. 3. 2018 15:34, Soňa Böhmová

Anotace

V originále

Unlike bone marrow bio psies, liquid bio psies represent a gentler, more accessible, less painful,repeatable and more comprehensive approach to get bio logically relevant information about the entire tumor but also about treatment response and level of minimal residual disease. This is all possible since peripheral blood contains not only circulating tumor cells but also many circulating molecules of nucleic acids (microRNA, cell-free DNA, long non-coding RNA etc.).Multiple myeloma is a genetically heterogeneous disease characterized by multifocal tumor deposits in the bone marrow but also focal lesions elsewhere. Single-site bio psy of the bone marrow creates a sampling bias that provides a limited molecular profile as the bio psy cannot capture all subclones. Moreover, during disease progression and treatment, molecular profile is changed and subclones of multiple myeloma cells resistant to treatment are formed. Likewise,various clones found in extramedullary sites that are not present in the bone marrow respond differently to treatment directly influencing survival of patients. Thus, liquid bio psies seem to be a relevant and necessary next step for diseases such as multiple myeloma.

Návaznosti

NV15-29508A, projekt VaV

Název: Cirkulující nukleové kyseliny jako markery progrese mnohočetného myelomu

Citovat

KUBACZKOVÁ, Veronika, Lenka SEDLAŘÍKOVÁ, Božena BOLLOVÁ, Viera SANDECKÁ, Martin ŠTORK, Luděk POUR a Sabina ŠEVČÍKOVÁ. Liquid Biopsies - The Clinics and the Molecules. Klinická onkologie. Praha: Ambit Media, 2017, roč. 30, Suppl. 2, s. "2S13"-"2S20", 8 s. ISSN 0862-495X. Dostupné z: https://dx.doi.org/10.14735/amko20172S13.

@article{1392121,
   author = {Kubaczková, Veronika and Sedlaříková, Lenka and Bollová, Božena and Sandecká, Viera and Štork, Martin and Pour, Luděk and Ševčíková, Sabina},
   article_location = {Praha},
   article_number = {Suppl. 2},
   doi = {http://dx.doi.org/10.14735/amko20172S13},
   keywords = {cell-free DNA non-coding RNA; liquid biopsies; minimal residual disease; multiple myeloma},
   language = {eng},
   issn = {0862-495X},
   journal = {Klinická onkologie},
   title = {Liquid Biopsies - The Clinics and the Molecules},
   volume = {30},
   year = {2017}
}

TY  - JOUR
ID  - 1392121
AU  - Kubaczková, Veronika - Sedlaříková, Lenka - Bollová, Božena - Sandecká, Viera - Štork, Martin - Pour, Luděk - Ševčíková, Sabina
PY  - 2017
TI  - Liquid Biopsies - The Clinics and the Molecules
JF  - Klinická onkologie
VL  - 30
IS  - Suppl. 2
SP  - "2S13"-"2S20"
EP  - "2S13"-"2S20"
PB  - Ambit Media
SN  - 0862495X
KW  - cell-free DNA non-coding RNA
KW  - liquid biopsies
KW  - minimal residual disease
KW  - multiple myeloma
N2  - Unlike bone marrow bio psies, liquid bio psies represent a gentler, more accessible, less painful,repeatable and more comprehensive approach to get bio logically relevant information about the entire tumor but also about treatment response and level of minimal residual disease. This is all possible since peripheral blood contains not only circulating tumor cells but also many circulating molecules of nucleic acids (microRNA, cell-free DNA, long non-coding RNA etc.).Multiple myeloma is a genetically heterogeneous disease characterized by multifocal tumor deposits in the bone marrow but also focal lesions elsewhere. Single-site bio psy of the bone marrow creates a sampling bias that provides a limited molecular profile as the bio psy cannot capture all subclones. Moreover, during disease progression and treatment, molecular profile is changed and subclones of multiple myeloma cells resistant to treatment are formed. Likewise,various clones found in extramedullary sites that are not present in the bone marrow respond differently to treatment directly influencing survival of patients. Thus, liquid bio psies seem to be a relevant and necessary next step for diseases such as multiple myeloma.
ER  -

KUBACZKOVÁ, Veronika, Lenka SEDLAŘÍKOVÁ, Božena BOLLOVÁ, Viera SANDECKÁ, Martin ŠTORK, Luděk POUR a Sabina ŠEVČÍKOVÁ. Liquid Biopsies - The Clinics and the Molecules. \textit{Klinická onkologie}. Praha: Ambit Media, 2017, roč.~30, Suppl. 2, s.~''2S13''-''2S20'', 8 s. ISSN~0862-495X. Dostupné z: https://dx.doi.org/10.14735/amko20172S13.

Podrobný výpis o publikaci